GoWit Builds the Largest Commerce and Retail Media Ecosystem in EMEA
30.9.2025 07:07:00 CEST | Business Wire | Press Release
GoWit, a global AdTech leader in omnichannel Retail Media, announced the launch of GoWit Commerce Media, a unified advertising platform connecting retailers, brands, and agencies. Replacing fragmented solutions, GoWit unites 7,000+ brands and agencies with leading retailers in more than 20 markets, creating the largest advertising network in EMEA. With Commerce Media projected to reach $220B by 2027, the platform provides advertisers and media owners with the scale, standardization, and simplicity they urgently need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250929777651/en/
GoWit Commerce & Retail Media Network
Breaking Industry Barriers
Retail Media is booming, yet adoption is slowed by fragmentation, high costs, and measurement gaps. According to IAB Europe, advertisers cite network fragmentation (51%) and lack of standardization (53%) as their biggest hurdles, while retailers point to operational setup (54%) and costs (40%).
GoWit solves these challenges by consolidating solutions into a single platform, simplifying operations, unlocking budgets, and driving measurable performance.
Powering Growth Through Partnerships
Partnerships are at the core of GoWit Commerce and Retail Media, where demand, technology, and ad operations merge into one connected ecosystem. Collaborations with Heureka Group, CarrefourSA, Beymen, Kingfisher (Koçtaş), Raneen, Mumzworld, and Toters Delivery bring unmatched scale across Europe and MENA. Technology and sales partnerships with Tooplay, The Trade Desk DSP, Akinon, Spike E-Media, Goldbach, and Craftware add advanced programmatic, local reach, and expertise.
- In Switzerland, Marc Meghji, BDM at Goldbach Group AG, added: “It’s truly reassuring to know we can count on such a competent and helpful partnership for our Swiss Retail Media journey.”
- “GoWit is the cornerstone powering Spike’s vision to elevate Commerce and Retail Media across the Middle East,” added Rami Taibah of Spike E-Media.
Unified Platform for Retailers, Brands, Agencies
GoWit’s AI-driven advertising hub enables:
- Retailers to integrate in minutes, activate omnichannel ads (display, sponsored listings, video, off-site, in-store), and tap into advertiser demand.
- Brands & Agencies to run multi-retailer campaigns with self-service tools for segmentation, automated bidding, and real-time reporting.
“The future of advertising belongs to those who connect commerce with data and context,” said Emrah Adsan, CEO of GoWit. “By creating the largest ecosystem in EMEA, we help every player transform data into scalable media opportunities.”
About GoWit
GoWit is the leading AdTech company building EMEA’s largest Commerce and Retail Media Network. Its platform combines best-in-class technology, ad operations, and demand to maximize monetization and relevancy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929777651/en/
Contacts
GoWit
Begench Soyunov
+905416333166
begench@gowit.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom